• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在口服霍乱疫苗现场试验中,不参与作为不良健康结局的一个决定因素。

Nonparticipation as a determinant of adverse health outcomes in a field trial of oral cholera vaccines.

作者信息

Clemens J D, van Loon F F, Rao M, Sack D A, Ahmed F, Chakraborty J, Khan M R, Yunus M, Harris J R, Svennerholm A M

机构信息

International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.

出版信息

Am J Epidemiol. 1992 Apr 15;135(8):865-74. doi: 10.1093/oxfordjournals.aje.a116382.

DOI:10.1093/oxfordjournals.aje.a116382
PMID:1585899
Abstract

The authors estimated the incidence rates of cholera and death between 1985 and 1988 for 32,642 age- and sex-eligible persons who did not participate in a randomized, placebo-controlled field trial of killed oral cholera vaccines in rural Bangladesh. As compared with 20,744 placebo recipients, the relative risk of cholera for all nonparticipants, adjusted for potentially confounding demographic variables, was 1.20 (95% confidence interval (CI) 1.03-1.41); this adjusted relative risk reflected elevated adjusted relative risks in nonparticipants who were medically ineligible (RR = 1.65; 95% CI 1.22-2.22) or refused to participate (RR = 1.19; 95% CI 1.01-1.41), but not in persons absent at the time of vaccination (RR = 1.00; 95% CI 0.78-1.28). The adjusted relative risk of death was also elevated in nonparticipants as compared with placebo recipients (RR = 1.28; 95% CI 1.10-1.48), with the same pattern of adjusted relative risks for different categories of nonparticipants: for ineligible subjects, 2.64 (95% CI 2.12-3.29); for refusers, 1.20 (95% CI 1.02-1.41); and for absentees, 0.95 (95% CI 0.75-1.22). The authors concluded that nonparticipation was associated with clinically cogent adverse health outcomes, but that the magnitude of these associations varied according to the reason for nonparticipation. These findings underscore the caution required in assessing vaccine efficacy with controls who are not vaccinated because of choices made by patients or vaccinators.

摘要

作者估算了1985年至1988年期间,孟加拉国农村地区32,642名符合年龄和性别的人群中霍乱发病率和死亡率,这些人未参与口服霍乱死疫苗的随机、安慰剂对照现场试验。与20,744名接受安慰剂者相比,在对潜在混杂人口统计学变量进行调整后,所有未参与者患霍乱的相对风险为1.20(95%置信区间[CI] 1.03 - 1.41);这种调整后的相对风险反映出,在医学上不符合条件的未参与者(RR = 1.65;95% CI 1.22 - 2.22)或拒绝参与者(RR = 1.19;95% CI 1.01 - 1.41)中,调整后的相对风险升高,但在接种时不在场的人群中未升高(RR = 1.00;95% CI 0.78 - 1.28)。与接受安慰剂者相比,未参与者调整后的死亡相对风险也升高(RR = 1.28;95% CI 1.10 - 1.48),不同类别的未参与者调整后的相对风险模式相同:不符合条件的受试者为2.64(95% CI 2.12 - 3.29);拒绝者为1.20(95% CI 1.02 - 1.41);不在场者为0.95(95% CI 0.75 - 1.22)。作者得出结论,未参与与临床上明显的不良健康后果相关,但这些关联的程度因未参与的原因而异。这些发现强调了在评估疫苗效力时,对于因患者或接种者的选择而未接种疫苗的对照组需要谨慎。

相似文献

1
Nonparticipation as a determinant of adverse health outcomes in a field trial of oral cholera vaccines.在口服霍乱疫苗现场试验中,不参与作为不良健康结局的一个决定因素。
Am J Epidemiol. 1992 Apr 15;135(8):865-74. doi: 10.1093/oxfordjournals.aje.a116382.
2
The design and analysis of cholera vaccine trials: recent lessons from Bangladesh.霍乱疫苗试验的设计与分析:来自孟加拉国的近期经验教训。
Int J Epidemiol. 1993 Aug;22(4):724-30. doi: 10.1093/ije/22.4.724.
3
Field trial of oral cholera vaccines in Bangladesh.孟加拉国口服霍乱疫苗现场试验
Lancet. 1986 Jul 19;2(8499):124-7. doi: 10.1016/s0140-6736(86)91944-6.
4
Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.孟加拉国口服霍乱疫苗现场试验:三年随访结果
Lancet. 1990 Feb 3;335(8684):270-3. doi: 10.1016/0140-6736(90)90080-o.
5
Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.越南一种本地生产的口服霍乱灭活疫苗的现场试验。
Lancet. 1997 Jan 25;349(9047):231-5. doi: 10.1016/s0140-6736(96)06107-7.
6
Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines.存在疫苗效力衰减情况下的疫苗效力评估:在霍乱疫苗中的应用
Am J Epidemiol. 1998 May 15;147(10):948-59. doi: 10.1093/oxfordjournals.aje.a009385.
7
Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh.一剂口服霍乱疫苗在孟加拉国的效果。
N Engl J Med. 2016 May 5;374(18):1723-32. doi: 10.1056/NEJMoa1510330.
8
Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis.孟加拉国口服霍乱死疫苗产生的群体免疫:重新分析
Lancet. 2005;366(9479):44-9. doi: 10.1016/S0140-6736(05)66550-6.
9
Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial.孟加拉国城市流行地区口服霍乱疫苗的可行性和有效性:一项整群随机开放标签试验。
Lancet. 2015 Oct 3;386(10001):1362-1371. doi: 10.1016/S0140-6736(15)61140-0. Epub 2015 Jul 9.
10
Breast feeding and the risk of severe cholera in rural Bangladeshi children.母乳喂养与孟加拉国农村儿童患严重霍乱的风险
Am J Epidemiol. 1990 Mar;131(3):400-11. doi: 10.1093/oxfordjournals.aje.a115515.

引用本文的文献

1
Quantifying the Population-Level Effect of the COVID-19 Mass Vaccination Campaign in Israel: A Modeling Study.量化以色列新冠大规模疫苗接种运动的人群水平效应:一项建模研究。
Open Forum Infect Dis. 2022 Feb 18;9(5):ofac087. doi: 10.1093/ofid/ofac087. eCollection 2022 May.
2
Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial.在孟加拉国使用口服霍乱全细胞灭活疫苗的效果:一项集群随机试验的进一步随访。
Lancet Infect Dis. 2021 Oct;21(10):1407-1414. doi: 10.1016/S1473-3099(20)30781-7. Epub 2021 Jun 16.
3
Positive Social Impacts Related to Participation in an HIV Prevention Trial Involving People Who Inject Drugs.
与参与涉及注射吸毒者的艾滋病毒预防试验相关的积极社会影响。
IRB. 2015 Jan-Feb;37(1):17-9.
4
Outcomes for patients with the same disease treated inside and outside of randomized trials: a systematic review and meta-analysis.随机试验内外治疗同一种疾病的患者的结局:系统评价和荟萃分析。
CMAJ. 2014 Nov 4;186(16):E596-609. doi: 10.1503/cmaj.131693. Epub 2014 Sep 29.
5
Oral vaccines for preventing cholera.用于预防霍乱的口服疫苗。
Cochrane Database Syst Rev. 2011 Mar 16;2011(3):CD008603. doi: 10.1002/14651858.CD008603.pub2.
6
Use of oral cholera vaccines in an outbreak in Vietnam: a case control study.在越南的疫情爆发中使用口服霍乱疫苗:一项病例对照研究。
PLoS Negl Trop Dis. 2011 Jan 25;5(1):e1006. doi: 10.1371/journal.pntd.0001006.
7
Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate.参与随机对照试验的患者与接受类似干预但未参与试验的类似患者的结局比较。
Cochrane Database Syst Rev. 2008 Jul 16;2008(3):MR000009. doi: 10.1002/14651858.MR000009.pub4.
8
Ethics and research in critical care.重症监护中的伦理与研究。
Intensive Care Med. 2006 Nov;32(11):1697-705. doi: 10.1007/s00134-006-0305-4. Epub 2006 Aug 8.
9
Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.用于预防A群脑膜炎球菌性脑膜炎的多糖疫苗。
Cochrane Database Syst Rev. 2005 Jan 25;2005(1):CD001093. doi: 10.1002/14651858.CD001093.pub2.